Cytek Biosciences (CTKB) Cash from Financing Activities (2020 - 2026)

Cytek Biosciences has reported Cash from Financing Activities for 7 years, with the latest figure at $4.0 million in Q1 2026.

• For the quarter ending Q1 2026, Cash from Financing Activities rose 134.48% year-over-year to $4.0 million; the trailing twelve-month figure through Mar 2026 stood at $2.1 million (up 107.23% YoY), and the FY2025 full-year result was -$13.4 million, up 15.11% from the prior year.
• Cash from Financing Activities for Q1 2026 stood at $4.0 million, up from -$1.2 million in the prior quarter.
• The five-year high for Cash from Financing Activities was $4.0 million in Q1 2026, with the low at -$33.8 million in Q4 2023.
• Historically, Cash from Financing Activities has averaged -$3.8 million across 5 years, with a median of -$535500.0 in 2022.
• Annual changes were most pronounced in 2022 — Cash from Financing Activities surged 22547.06% — and 2023, when it sank 5438.06%.
• Cytek Biosciences' Cash from Financing Activities stood at $3.8 million in 2022, then plunged by 976.73% to -$33.8 million in 2023, then jumped by 89.22% to -$3.6 million in 2024, then jumped by 66.32% to -$1.2 million in 2025, then surged by 424.71% to $4.0 million in 2026.
• The last three Cash from Financing Activities figures came in at $4.0 million (Q1 2026), -$1.2 million (Q4 2025), and $1.9 million (Q3 2025), per Business Quant data.